Supported by evidence showing that DC-derived IL-1β-dependent priming of CD8+ T cells augments their tumoricidal properties and that Nlrp3-/- or Casp-1-/- DCs sub-optimally prime T cells (132), these data suggest that IL-1β (or potentially IL-1α) depletion from the tumor microenvironment could confer immunosuppression and poor tumor control, and thus IL-1R2 expression on intra-tumoral Tregs could be utilized as a prognostic marker. The gene discussed is IL1B; the disease is neoplasm.